Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications
Open Access
- 6 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 20 (1), 1-13
- https://doi.org/10.1186/s12885-020-06882-6
Abstract
The microbiome has been shown to affect the response to Immune Checkpoint Inhibitors (ICIs) in a small number of cancers and in preclinical models. Here, we sought to broadly survey cancers to identify those in which the microbiome may play a prognostic role using retrospective analyses of patients with advanced cancer treated with ICIs. We conducted a retrospective analysis of 690 patients who received ICI therapy for advanced cancer. We used a literature review to define a causal model for the relationship between medications, the microbiome, and ICI response to guide the abstraction of electronic health records. Medications with precedent for changes to the microbiome included antibiotics, corticosteroids, proton pump inhibitors, histamine receptor blockers, non-steroid anti-inflammatories and statins. We tested the effect of medication timing on overall survival (OS) and evaluated the robustness of medication effects in each cancer. Finally, we compared the size of the effect observed for different classes of antibiotics to taxa that have been correlated to ICI response using a literature review of culture-based antibiotic susceptibilities. Of the medications assessed, only antibiotics and corticosteroids significantly associated with shorter OS. The hazard ratios (HRs) for antibiotics and corticosteroids were highest near the start of ICI treatment but remained significant when given prior to ICI. Antibiotics and corticosteroids remained significantly associated with OS even when controlling for multiple factors such as Eastern Cooperative Oncology Group performance status, Charlson Comorbidity Index score, and stage. When grouping antibiotics by class, β-lactams showed the strongest association with OS across all tested cancers. The timing and strength of the correlations with antibiotics and corticosteroids after controlling for confounding factors are consistent with the microbiome involvement with the response to ICIs across several cancers.Keywords
Funding Information
- National Center for Advancing Translational Sciences (8UL1TR000090-05)
- National Cancer Institute (2 P30 CA016058-42, 5K12 CA133250-09)
- Pelotonia New Investigator (.)
This publication has 48 references indexed in Scilit:
- The impact of anti-inflammatory agents on the outcome of patients with colorectal cancerCancer Treatment Reviews, 2014
- The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell HomeostasisScience, 2013
- Gut microbiota disturbance during antibiotic therapy: a multi-omic approachGut, 2012
- Diversity, stability and resilience of the human gut microbiotaNature, 2012
- Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapyPharmacological Research, 2012
- Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbationProceedings of the National Academy of Sciences of the United States of America, 2010
- The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patientsJournal of Clinical Epidemiology, 2008
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2008
- Drugs, inflammation and cell adhesion receptorsExpert Opinion on Pharmacotherapy, 2001
- Validation of a combined comorbidity indexJournal of Clinical Epidemiology, 1994